Published in Cancer on March 01, 2009
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 3.62
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med (2012) 1.85
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol (2012) 1.29
Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis (2016) 0.93
The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol (2010) 0.84
Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. Br J Cancer (2013) 0.83
Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis. J Ovarian Res (2014) 0.82
Restricting carbohydrates to fight head and neck cancer-is this realistic? Cancer Biol Med (2014) 0.80
Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. J Cancer (2016) 0.78
Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. Oncotarget (2016) 0.77
Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol (2017) 0.76
Sugar fuels cancer. Cancer (2009) 0.75
Novel predictive biomarkers for cervical cancer prognosis. Mol Clin Oncol (2016) 0.75
Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer. PLoS One (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Standards of medical care in diabetes--2007. Diabetes Care (2007) 12.35
Reactive oxygen species: a breath of life or death? Clin Cancer Res (2007) 4.20
Abnormal glucose metabolism and pancreatic cancer mortality. JAMA (2000) 4.01
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Postprandial blood glucose. American Diabetes Association. Diabetes Care (2001) 3.38
Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol (2006) 2.76
Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev (1997) 2.39
Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res (2006) 2.27
Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci (2000) 2.25
Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol (2005) 2.15
2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res (2007) 2.03
Enzymology of cancer cells (second of two parts). N Engl J Med (1977) 2.00
Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem (2004) 1.94
The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res (2003) 1.67
Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia (1999) 1.33
Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther (2005) 1.28
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer (2001) 1.27
Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose. Cancer Res (2006) 1.25
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer (2007) 1.11
Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys (2007) 1.11
Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther (2005) 1.08
GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology (2004) 0.94
Prognostic value of Ca 125 levels during primary therapy. Anticancer Res (2007) 0.86
2-Deoxyglucose and radiosensitization: teaching an old DOG new tricks? Cancer Biol Ther (2006) 0.86
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell (2008) 6.16
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell (2010) 5.40
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell (2010) 4.19
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res (2002) 3.29
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 2.73
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 2.72
Active choice but not too active: public perspectives on biobank consent models. Genet Med (2011) 2.57
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J (2009) 2.35
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res (2006) 2.27
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int J Biol Sci (2008) 2.12
Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail (2009) 2.10
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand (2002) 2.04
2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res (2007) 2.03
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem (2004) 1.94
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol (2010) 1.88
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Theophylline improves esophageal chest pain--a randomized, placebo-controlled study. Am J Gastroenterol (2007) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol (2008) 1.86
Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res (2011) 1.84
Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology (2010) 1.84
Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys (2009) 1.83
Role of glutaredoxin in metabolic oxidative stress. Glutaredoxin as a sensor of oxidative stress mediated by H2O2. J Biol Chem (2002) 1.82
Oxidative metabolism modulates signal transduction and micronucleus formation in bystander cells from alpha-particle-irradiated normal human fibroblast cultures. Cancer Res (2002) 1.80
Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol (2003) 1.80
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
New national liver transplant allocation policy: is the regional review board process fair? Liver Transpl (2004) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Predictors of weight loss in Parkinson's disease. Mov Disord (2006) 1.76
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med (2011) 1.74
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun (2008) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination. Arch Ophthalmol (2005) 1.64
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. Cancer Res (2003) 1.62